We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.965 | 2.33% | 42.405 | 42.84 | 42.31 | 42.70 | 2,221,722 | 17:52:31 |
From May 2021 to May 2024
By Cecilia Butini
GlaxoSmithKline PLC said Wednesday that net profit dropped in the second quarter compared with the previous year, though sales grew on-year and it backed its outlook for the full year.
The British pharmaceutical major posted net profit of 1.40 billion pounds ($1.94 billion) for the period, down from GBP2.26 billion the year prior. Adjusted earnings per share were 28.1 pence, compared with 19.2 pence in the same period a year earlier.
Sales came in at GBP8.09 billion, up from GBP7.62 billion in the second quarter of 2020, when both pharmaceuticals and vaccine sales were affected by the pandemic.
The company backed a previously given outlook for 2021, saying that it expects adjusted EPS to decline by mid-to-high single-digit percentage at constant exchange rates. Looking at 2022, it said it expects meaningful improvements in revenues and margins.
GlaxoSmithKline declared a dividend of 19 pence a share for the second quarter, adding that it continues to expect a dividend of 80 pence a share for the full year 2021.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
July 28, 2021 07:39 ET (11:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
